Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Breast Cancer
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1497272
This article is part of the Research Topic Advances in Tumor Microenvironment, Immunology and Immunotherapy of Breast Cancer View all 8 articles

Br east Acinic Cell Car cinoma with Weak Pr ogester one Receptor Expr ession: A Case Repor t and Liter atur e Review

Provisionally accepted
Fan Zhimin Fan Zhimin 1*Caiyun Bai Caiyun Bai 2*JingChun Han JingChun Han 3*Yisen Yang Yisen Yang 2*Fengjiang Qu Fengjiang Qu 4*
  • 1 Breast Surgery Department, fanzm@jlu.edu.cn, First Affiliated Hospital of Jilin University, Changchun, China
  • 2 Breast Surgery Department, First Affiliated Hospital of Jilin University, Changchun, China
  • 3 Emergency internal medicineDepartment, First Affiliated Hospital of Jilin University, Changchun, China
  • 4 Energency Surgery Department, First Affiliated Hospital of Jilin University, Changchun, China

The final, formatted version of the article will be published soon.

    Rationale: Acinic cell carcinoma (AcCC) of the breast is an extremely rare malignant epithelial tumor characterized by acini cell differentiation, clinical low-grade malignancy, and a molecular triple-negative subtype.A 47-year-old female presented with a 1-month history of a painless mass in her right breast. Diagnosis: Ultrasound imaging, mammography and magnetic resonance imaging revealed a lesion, approximately 3.0cm×1.5cm in size, in the right breast, which was considered to be a malignancy. After the surgery, the AcCC of the breast was confirmed histologically.Right breast mastectomy and sentinel lymph node biopsy were performed. Adjuvant chemotherapy included 4 cycles of doxorubicin hydrochloride (Adriamycin) and cyclophosphamide followed by 4 cycles of docetaxel (Taxotere).The patient was discharged from the hospital after surgery. There was no sign of recurrence during a 9-month follow-up period. Lessons: Acinic cell carcinoma (AcCC) of the breast is an extremely rare malignant epithelial tumor that can be accurately diagnosed based on histopathologic morphology and immunohistochemistry. The weak positive progesterone receptor (PR) expressed in this case is extremely rare, which may provide a new research direction for the endocrine therapy of AcCC. Both AcCC and microglandular adenosis(MGA) exhibit microglandular growth, and the relationship between them remains unclear. Differentiation between them not only relies on histomorphology and pathological immunohistochemistry but also depends on clinical manifestations and other presentations. Optimal treatment of AcCC is the same as that for invasive breast cancer. The prognosis is generally good, with adjuvant therapy after surgery.

    Keywords: breast cancer, Acinic cell carcinoma, Progesterone Receptor, Adjuvant chemotherapy, microglandular adenosis

    Received: 16 Sep 2024; Accepted: 23 Dec 2024.

    Copyright: © 2024 Zhimin, Bai, Han, Yang and Qu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Fan Zhimin, Breast Surgery Department, fanzm@jlu.edu.cn, First Affiliated Hospital of Jilin University, Changchun, China
    Caiyun Bai, Breast Surgery Department, First Affiliated Hospital of Jilin University, Changchun, China
    JingChun Han, Emergency internal medicineDepartment, First Affiliated Hospital of Jilin University, Changchun, China
    Yisen Yang, Breast Surgery Department, First Affiliated Hospital of Jilin University, Changchun, China
    Fengjiang Qu, Energency Surgery Department, First Affiliated Hospital of Jilin University, Changchun, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.